Progress in clinical research of Claudin-18.2 targeted therapy for advanced gastric cancer
10.3781/j.issn.1000-7431.2024.2305-0227
- VernacularTitle:晚期胃癌Claudin-18.2靶向治疗临床研究新进展
- Author:
Yiyi YU
1
;
Xiao WANG
;
Tianshu LIU
Author Information
1. 复旦大学附属中山医院肿瘤内科,上海 200032;复旦大学附属中山医院肿瘤防治中心,上海 200032
- Keywords:
Advanced gastric cancer;
Claudin-18.2;
Targeted therapy;
CAR-T
- From:
Tumor
2024;44(1):34-43
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is one of the most common malignant tumors of the digestive system.Most gastric cancer patients are already in advanced stage when initially diagnosed.Advanced gastric cancer has a poor prognosis and has received limited benefit from chemotherapy-based therapies.In the recent years,with the development of biomolecular technologies,more and more researches have set their focus on the search for key molecules that affect the progression of gastric cancer,prognostic indicators,and therapeutic targets.Claudin-18.2 is a promising novel tumor therapeutic target which brings new hope for targeted therapy for gastric cancer.Various types of Claudin-18.2-targeting drugs have been developed,including monoclonal antibody,bispecific antibody(BsAb),antibody-drug conjugate(ADC),chimeric antigen receptor T cell(CAR-T),and so on.At present,several clinical trials have been carried out and the results are encouraging.This review summarizes the progress in clinical trials of Claudin-18.2 targeted therapy,in the hope to provide reference for improving the prognosis of patients with advanced gastric cancer.
